VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment




VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment

• Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities
• VarmX shareholders to receive initial $117m upfront and further potential milestone payments up to $2.1bn
• Transformational step for VarmX, well positioned to bring VMX-C001 to patients
• Exclusive option agreement for CSL to acquire all issued and outstanding shares of the company, dependent on Phase 3 data

LEIDEN, Netherlands–(BUSINESS WIRE)–VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has entered into a strategic collaboration with global biotechnology leader, CSL (ASX:CSL), to support the development of its lead asset, VMX-C001. VMX-C001 is a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs. CSL has also entered into an exclusive option agreement with VarmX shareholders to acquire all issued and outstanding shares of the company.

Under the terms of the strategic collaboration agreement, CSL will fully fund VarmX’s global Phase 3 EquilibriX-S trial evaluating VMX-C001 in patients taking FXa DOACs who require urgent surgery. CSL will also fully fund and support VarmX in late-stage product development, manufacturing and pre-launch commercial and medical affairs activities.

CSL will make an upfront payment to VarmX shareholders of USD 117 million upon closing of the transaction for an exclusive option to acquire the company. CSL will have the right to exercise the option upon Phase 3 data. Subject to the achievement of certain milestones, following the exercise of the option and customary regulatory clearances, VarmX shareholders will receive a further USD 388 million in acquisition and additional payments up to the commercial launch of VMX-C001 and up to USD 1.7 billion in sales-based success milestones thereafter.

John Glasspool, Chief Executive Officer of VarmX, said:

“The collaboration with CSL represents a transformative step for VarmX. By securing full funding for the registrational trial, product development, CMC and pre-launch activities, we are well positioned to bring VMX-C001 to patients. We are proud to partner with CSL, whose expertise and global reach will be invaluable as we move forward.”

Dr. Paul McKenzie, Chief Executive Officer of CSL, commented:

“We are excited to partner with VarmX to develop a novel treatment and address a significant unmet need aligning strongly with our strategic ambition to deliver enduring patient impact. It also aligns with our portfolio of medicines designed to minimize bleeding, preserve a patient’s own blood supply, improve surgical and medical outcomes and support global public health approaches to patient blood management.”

Bill Mezzanotte, CSL Executive Vice President and Head of Research & Development, added:

“CSL was particularly interested in VMX-C001’s unique mechanism of action, how it specifically targets Factor Xa inhibitors, compared to the more general action of other treatments, and the preclinical and early clinical data which led to U.S Food and Drug Administration (FDA) approval to proceed straight to a single Phase 3 study.”

VMX-C001 is an investigational, recombinant modified Factor X protein administered as a rapid single-dose, effectively bypassing the FXa anticoagulation activity and swiftly restoring coagulation in patients on Factor Xa inhibitors in urgent surgery and severe bleeding situations. It could offer the potential to be used with all FXa DOACs and be administered with other common anticoagulants like heparin, and potentially, with no additional thrombotic risk.

By 2030, an estimated 30 million patients in the US, Europe, and Japan will be on Factor Xa (FXa) direct oral anticoagulants (DOACs) for chronic indications such as stroke prevention in atrial fibrillation and treatment of deep vein thrombosis. While these therapies are highly effective, 2-4% of patients each year face severe, life-threatening bleeding or require emergency surgery, amounting to more than 30,000 affected patients every week.

Despite the unmet clinical need, no fully approved therapeutic agent is currently available in the E.U. or the U.S. for treating acute major bleeding in patients on Factor Xa inhibitors.

VMX-C001 was recently granted Fast Track Designation by the FDA, as announced on 3 September 2025, recognizing its potential to address a critical unmet medical need in restoring coagulation for patients on FXa DOACs requiring urgent surgery. Commercial launch is anticipated in 2029.

John Glasspool, Chief Executive Officer of VarmX concluded:

“We are grateful for the continued support of our investors, including Sound Bioventures, EIC, EQT Life Sciences, INKEF, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, InnovationQuarter, LEH and UNIIQ, who share our vision of transforming urgent care for patients and have been instrumental in helping the company grow and reach this milestone.”

UBS AG is acting as the exclusive financial advisor to VarmX. NautaDutilh N.V. is acting as legal advisor to VarmX.

Notes to Editors

About VarmX

VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter. For more information, please visit www.varmx.com.

About VMX-C001

VMX-C001 is a modified, human, factor X protein, designed to be insensitive to FXa DOACs, effectively bypassing their anticoagulant activity and swiftly restoring the coagulation cascade.VMX-C001 has been developed with significant clinical advantages, including universal dosing regardless of the specific FXa DOAC used, rapid and easy administration, compatibility with common anticoagulants like heparin, and crucially, no additional thrombotic risk.

About CSL

CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL, visit www.CSL.com.

Contacts

For further information, please contact:
Vigo Consulting (media enquiries)
Rozi Morris

+44 20 7390 0230

VarmX@vigoconsulting.com

Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody




Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody

BEIJING–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previously signed research collaboration and option agreement to discover and advance antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery engine.

The antibody was generated using Biocytogen’s proprietary RenMice^® platform and features high affinity, low immunogenicity, and favorable developability. Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies based on this antibody, aiming to address areas of high unmet clinical need in cancer treatment.

Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased that Tubulis has exercised its option, which reflects the international competitiveness and translational potential of our fully human antibody discovery platform. We look forward to seeing this antibody advance through Tubulis’ powerful ADC development engine and into clinical development to benefit patients around the world.”

Jonas Helma-Smets, PhD, CSO and co-founder of Tubulis, stated: “Our goal is to drive innovation in ADC development and deliver uniquely positioned ADC therapeutics that can improve treatment outcomes to patients with solid tumors. The R&D collaboration with Biocytogen has yielded an antibody candidate that we believe fits well with our ADC technology platforms and that may support us in the development of a novel therapeutic candidate.”

Under the terms of the agreement, Biocytogen will receive an upfront payment and is eligible for certain development, regulatory, and commercial milestone payments, and single-digit royalties on net sales.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice^® (RenMab^™/ RenLite^®/ RenNano^®/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice^® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

Contacts

Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody




Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody

BEIJING–(BUSINESS WIRE)–#ADCTherapeutics–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that ADC therapeutics developer, Tubulis has exercised an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. The antibody will be applied in a novel ADC candidate proprietary to Tubulis. It is part of a previously signed research collaboration and option agreement to discover and advance antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery engine.

The antibody was generated using Biocytogen’s proprietary RenMice^® platform and features high affinity, low immunogenicity, and favorable developability. Tubulis will apply its proprietary linker and payload technologies to develop innovative ADC therapies based on this antibody, aiming to address areas of high unmet clinical need in cancer treatment.

Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased that Tubulis has exercised its option, which reflects the international competitiveness and translational potential of our fully human antibody discovery platform. We look forward to seeing this antibody advance through Tubulis’ powerful ADC development engine and into clinical development to benefit patients around the world.”

Jonas Helma-Smets, PhD, CSO and co-founder of Tubulis, stated: “Our goal is to drive innovation in ADC development and deliver uniquely positioned ADC therapeutics that can improve treatment outcomes to patients with solid tumors. The R&D collaboration with Biocytogen has yielded an antibody candidate that we believe fits well with our ADC technology platforms and that may support us in the development of a novel therapeutic candidate.”

Under the terms of the agreement, Biocytogen will receive an upfront payment and is eligible for certain development, regulatory, and commercial milestone payments, and single-digit royalties on net sales.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice^® (RenMab^™/ RenLite^®/ RenNano^®/ RenTCR mimic^™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics^™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice^® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

Contacts

Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions




Paysign, Inc. Announces Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

HENDERSON, Nev.–(BUSINESS WIRE)–Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today posted the following summary notice of pendency and proposed settlement of stockholder derivative actions.

To: All Record Holders and Beneficial Owners of Paysign, Inc. (“Paysign” of the “Company”) Common Stock as of November 25, 2024.

Please read this summary notice carefully and in its entirety and as your rights may be affected by proceedings in the litigation.

YOU ARE HEREBY NOTIFIED that the following stockholder derivative actions (the “Derivative Actions”), are being settled on the terms set forth in a Stipulation and Agreement of Settlement dated November 25, 2024 (the “Stipulation”): (i) the above-captioned consolidated action, titled Toczek v. Newcomer et al, Case No. 2:20-cv-01722-JCM-NJK; (ii) Blanchette v. Paysign, Inc. et al., Case No. 2:23-cv-01632-JCM-BNW (D. Nev.); and (iii) Jeewa v. Newcomer, et al., Case No. 2:23-cv-02129-RFB-EJY (D. Nev.).

The Derivative Actions allege that, inter alia, between March 12, 2019 through September 17, 2020, at least, the Individual Defendants breached their fiduciary duties by issuing and/or causing the Company to issue materially false and misleading statements (including by soliciting a materially false and misleading proxy statement allegedly in violation of Section 14(a) of the Securities Exchange Act of 1934) and by failing to disclose material facts to the public regarding, among other things, that: (1) the Company failed to design, implement, and maintain effective IT general controls, specifically pertaining to user access and the Company’s systems change management; (2) the Company failed to maintain effective disclosure controls and internal controls over its financial reporting; and (3) due to the foregoing, the Company would be forced to delay filing its 2019 10-K and holding its 2019 year-end earnings call. The Derivative Actions also allege that the Individual Defendants breached their fiduciary duties by failing to correct and/or causing the Company to fail to correct these false and misleading statements and omissions of material fact to the investing public, while four of the Individual Defendants engaged in lucrative insider sales, netting combined proceeds of over $5.7 million. The Derivative Actions allege that, as a result of the foregoing, the Company experienced reputational and financial harm. Defendants have denied and continue to deny each and all of the claims and allegations of wrongdoing asserted in the Derivative Actions.

Pursuant to the terms of the Settlement, Paysign agrees to implement and maintain certain corporate governance reforms that are outlined in Exhibit A to the Stipulation (the “Reforms”). The Reforms shall be maintained for five (5) years. Paysign acknowledges and agrees that the filing, pendency, and settlement of the Derivative Actions was the cause of the Company’s decision to adopt, implement, and maintain the Reforms. Paysign also acknowledges and agrees that the Reforms confer substantial benefits to Paysign and its shareholders.

After negotiating the principal terms of the Settlement, counsel for the Parties, with the assistance of the Mediator, negotiated the attorneys’ fees and expenses to be paid to Plaintiffs’ Counsel, subject to Court approval (the “Fee and Expense Amount”). In light of the substantial benefits conferred upon the Company and its stockholders, Defendants’ insurers shall pay to Plaintiffs’ Counsel $607,500.00 for their attorneys’ fees and expenses, subject to Court approval. Defendants also agreed not to object to the request for the Court to approve Service Awards of up to two thousand dollars ($2,000.00) for each of the four Plaintiffs, to be paid from the Fee and Expense Amount.

On November 14, 2025 at 1:00 p.m., a hearing (the “Settlement Hearing”) will be held before the Honorable Richard F. Boulware at the United States District Court for the District of Nevada, Las Vegas Division, 333 Las Vegas Boulevard South, Las Vegas, Nevada 89101, for the purpose of determining whether the Settlement should be approved as fair, reasonable, and adequate and whether the Court should approve the agreed-to Fee and Expense Amount and the Service Awards for Plaintiffs. Because this is not a class action, except as otherwise provided for in the Stipulation with respect to the Plaintiffs, no Current Paysign Stockholder has the right to receive any individual compensation as a result of the Settlement.

This Summary Notice provides a condensed overview of certain provisions of the Stipulation and the full Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions (the “Notice”). It is not a complete statement of the events of the Derivative Actions or the terms set forth in the Stipulation. This summary should be read in conjunction with, and is qualified in its entirety by reference to, the text of the Stipulation. For additional information about the claims asserted in the Derivative Actions, and the terms of the proposed Settlement, you may inspect the full Notice and the Stipulation and its exhibits and other papers at the Clerk’s office in the Court at any time during regular business hours. In addition, copies of the Stipulation and its exhibits and the Notice are available on the Investor Relations page of the Company’s website, www.paysign.com.

The Court may, in its discretion, change the date, time, or format of the Settlement Hearing without further notice to you. If you intend to attend the Settlement Hearing, please consult the Court’s calendar or Investor Relations page of the Company’s website, www.paysign.com, for any change in the date, time, or format of the Settlement Hearing.

Inquiries about the Derivative Actions or the Settlement may be made to: Timothy Brown, The Brown Law Firm, P.C., 767 Third Avenue, Suite 2501, New York, NY 10017, Telephone: (516) 922-5427, Email: tbrown@thebrownlawfirm.net.

You may enter an appearance before the Court, at your own expense, individually or through counsel of your choice. If you want to object at the Settlement Hearing, you must be a Current Paysign Stockholder and you must first comply with the procedures for objecting that are set forth in the Notice. Any objection to any aspect of the Settlement must be filed with the Clerk of the Court and sent to Plaintiffs’ Counsel and Defendants’ Counsel no later than October 24, 2025 (21 days before the Settlement Hearing), in accordance with the procedures set forth in the Stipulation and the Notice. Any Current Paysign Stockholder who fails to object in accordance with such procedures will be bound by the Order and Final Judgment of the Court granting final approval to the Settlement and the releases of claims therein, and shall be deemed to have waived the right to object (including the right to appeal) and forever shall be barred, in this proceeding or in any other proceeding, from raising such objection.

PLEASE DO NOT CALL THE COURT OR DEFENDANTS WITH QUESTIONS ABOUT THE SETTLEMENT.

About Paysign

Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

Contacts

Investor Relations

ir@paysign.com
888.522.4853

paysign.com/investors

Media Relations

Alicia Ches

888.522.4850

pr@paysign.com

Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development




Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

MATAWAN, N.J.–(BUSINESS WIRE)–Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego’s Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry.

Future Labs is part of Apimeds’ ai² innovation platform, connecting university students with real-world strategy and business development projects. Through this collaboration, student teams will work closely with Apimeds mentors to identify and evaluate opportunities to advance development projects previously left behind by industry.

“We’re thrilled to welcome University of San Diego students into the Future Labs program,” said Erik Emerson, CEO of Apimeds. “USD represents exactly the type of forward-thinking institution we want to partner with—where students are encouraged to bring fresh perspectives to complex problems. Drug development is challenging, and many therapies with true potential never reach patients. Future Labs is meant to function as both a discovery engine for assets and a training ground for tomorrow’s leaders.”

Students will gain hands-on experience in market analysis, FDA regulations, clinical development requirements, competitive positioning, intellectual property, and commercialization planning—skills that extend far beyond the classroom. Top-performing teams at each participating institution will be eligible for paid internships or consulting opportunities with Apimeds, creating a direct pathway into the industry.

“As a recent graduate of the University of San Diego, I see Future Labs as an incredible way to take what we’ve learned in the classroom and apply it directly to the challenges of the biopharma industry,” said Coben Emerson, Manager, FP&A, Apimeds. “By working hands-on with asset evaluation and strategy, students not only contribute to Apimeds’ pipeline exploration but also gain the kind of practical, career-ready experience that sets us apart as we enter the workforce.”

“Our students will gain invaluable exposure to the business side of the life sciences industry,” said Jaime Alonso Gomez, PhD, professor of strategy, international management and family business at the Knauss School of Business. “Partnering with Apimeds allows us to deliver a one-of-a-kind experience—where academic rigor meets real-world biopharma decision-making.”

The initiative underscores Apimeds’ commitment to fostering innovation, building meaningful industry–academic collaborations, and shaping the next generation of biotech leaders.

About Apimeds Pharmaceuticals

Apimeds Pharmaceuticals (NYSE American: APUS) is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. The company’s lead product candidate, Apitox, is in late-stage clinical development for osteoarthritis of the knee. For more information visit www.apimedsus.com. Information on the Apimeds’ website does not constitute a part of and is not incorporated by reference into this press release.

About the Knauss School of Business, University of San Diego

The Knauss School of Business at the University of San Diego is committed to developing socially responsible leaders with a global mindset through values-based education and innovative research. Together, we work to advance sustainable and ethical business solutions that address the world’s greatest challenges.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds’ results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds’ ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on April 15, 2025 (as amended on May 2, 2025).

Contacts

Media Contact:
Brian Peters

Apimeds Pharmaceuticals

919-602-6557

Genesee Scientific Acquires Jade Scientific, Expanding Capabilities in Lab Essentials Market




Genesee Scientific Acquires Jade Scientific, Expanding Capabilities in Lab Essentials Market

The acquisition strengthens portfolio, broadens customer reach, and accelerates Genesee’s growth strategy

SAN DIEGO–(BUSINESS WIRE)–#BetterTogether—Genesee Scientific, a leading provider of high-quality, value-driven lab essentials, today announced the acquisition of Jade Scientific, a Michigan-based distributor recognized for its extensive offering of chemicals and consumables to clinical reference, pharma/biotech, and environmental labs nationwide.

This strategic acquisition marks a significant milestone in Genesee’s growth journey. Together, the two companies will expand product offerings, strengthen customer relationships, and reinforce Genesee’s position as a trusted partner for scientists across academia, biotech, and diagnostic labs.

“We are thrilled to welcome Jade Scientific into the Genesee family,” said Dan Monahan, CEO of Genesee Scientific. “Jade has built an exceptional reputation for customer service and quality. Together, we will broaden our ability to deliver essential products to scientists – while staying true to our mission of providing extraordinary value and uncompromising quality.”

Founded in 1995, Jade Scientific has served the scientific community for three decades, earning customer loyalty through strong relationships, deep product expertise, and an unwavering commitment to service.

“Joining forces with Genesee Scientific is an exciting opportunity for Jade, our employees, and our customers,” said Mike Smolin, CEO of Jade Scientific. “We share the same focus on quality, service, and supporting science. With Genesee’s scale and resources, we can deliver even greater value to customers while creating new opportunities for our team.”

The acquisition underscores Genesee’s strategy to accelerate growth through both organic initiatives and strategic partnerships. Customers of both companies will continue to receive the same personalized service they trust, while gaining access to a broader, more cost-efficient portfolio of lab essentials.

About Genesee Scientific

Genesee Scientific is a leading provider of lab essentials, delivering high-quality consumables, equipment, and private-label solutions to researchers in academic institutions, biotechnology, and diagnostic labs. Genesee’s mission is to serve scientists with extraordinary value in the everyday fundamentals of science.

About Jade Scientific

Founded in 1995, Jade Scientific is a trusted distributor of chemicals and consumables, serving clinical reference, pharma/biotech, industrial and environmental labs. With a reputation for reliability and service, Jade has supported scientists nationwide for 30 years.

Contacts

Media Contact
Sarah Kinsella

Head of Marketing, Genesee Scientific

SKinsella@GeneseeSci.com

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)




Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock option to purchase an aggregate of 440,000 shares of its common stock to Personalis’ new Senior Vice President, Chief Information Officer under Personalis’ 2020 Inducement Plan.

The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Personalis is making this announcement as required by Nasdaq rules.

The inducement stock option granted on September 15, 2025 has an exercise price of $5.93 per share, which is equal to the closing price of Personalis’ common stock on the grant date. The inducement stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and 1/36th of the remaining shares vesting monthly thereafter, subject to continued service through each applicable vesting date. The foregoing inducement award is subject to the terms and conditions of Personalis’ 2020 Inducement Plan, and the terms and conditions of the applicable award agreement covering the grant.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Contacts

Investors:
Caroline Corner

investors@personalis.com
415-202-5678

Media:
pr@personalis.com

Thermo Fisher Scientific Expands Neurodegeneration Research Capabilities with Launch of Olink® Target 48 Neurodegeneration Panel




Thermo Fisher Scientific Expands Neurodegeneration Research Capabilities with Launch of Olink® Target 48 Neurodegeneration Panel

Targeted proteomics panel delivers absolute quantification of key and emerging biomarkers in one scalable assay

WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Olink® Target 48 Neurodegeneration panel, a high-performance, targeted proteomics immunoassay panel developed to accelerate discoveries in neurodegenerative disease research. With diseases such as Alzheimer’s, multiple sclerosis and Parkinson’s on the rise and clinical pipelines eager for translational biomarkers, researchers face a pressing need for scalable, reproducible and disease-relevant protein measurement. This panel delivers simultaneous measurement of 41 key and emerging proteins for neurodegeneration research with absolute quantification and optimized for plasma measurement from as little as 1µL of sample.

The Target 48 Neurodegeneration panel is the latest addition to Olink’s growing portfolio of multiplex disease panels with absolute quantification readouts. Alongside the Olink® Target 48 Cytokine, Olink® Target 48 Immune Surveillance, and the semi-custom Olink® Flex platform, this solution helps create a powerful ecosystem for proteomics research. When combined, these panels allow researchers to seamlessly analyze a larger library of protein biomarkers that can help provide comprehensive insights into neurodegeneration and inflammation in the body.

An early access user, Charlotte Teunissen, professor in neurochemistry at the Department of Laboratory Medicine at Amsterdam University Medical Center, shared, “The Target 48 Neurodegeneration panel is a critical tool that enables the detection and quantification of key and emerging neurodegenerative disease biomarkers from plasma and cerebrospinal fluid samples. By generating quantitative data, it ensures reproducible results across and within longitudinal studies, moving a step forward towards clinical utilization.”

“Neurological diseases are complex, multifactorial and urgently in need of translational insights especially with non-invasive proteomic biomarkers for longitudinal monitoring,” said Yan Zhang, President of the Proteomic Sciences business at Thermo Fisher Scientific. “The panel, designed in close collaboration with leading clinical researchers, offers absolute quantification of multiplex key biomarkers to monitor disease progression and therapeutic responses to power precision medicine.”

Key benefits of the Olink® Target 48 Neurodegeneration include:

• Targeted depth: 41 protein biomarkers selected for relevance across Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease and other neurodegenerative disorders.
• Absolute quantification: Ability to quantify key and emerging biomarkers for neurodegeneration research simultaneously in one panel.
• Minimal sample input: Enables high-throughput studies with precious or biobank samples.
• Scalability and standardization: Compatible with Thermo Fisher’s global network of Olink-equipped labs for reproducibility across sites, critical for multi-center trials and large consortia.
• Proven solution: Uses Olink’s gold-standard Proximity Extension Assay (PEA) technology.

The new panel reinforces Thermo Fisher’s commitment to advancing precision medicine and neurology research, joining the company’s broader suite of tools spanning mass spectrometry, cryo-electron microscopy, and multiplex immunoassays. It builds on recent initiatives such as the UK Biobank proteomics program, the Geisinger Health Study with the Regeneron Genetics Center and cross-platform collaborations with leading biopharma companies.

The Olink® Target 48 Neurodegeneration has been developed with the aim of reducing import barriers such as long lead-times for importing into geographies with blood or plasma-derived import licenses. The Olink® Target 48 Neurodegeneration panel is fully compatible with the Olink® Signature Q100 benchtop system, providing a simplified workflow, minimal instrument maintenance and streamlined quality control, enabling laboratories to accelerate their biomarker research.

To learn more about the Olink® Target 48 Neurodegeneration Panel, please visit our website and register for the webinar on September 17, 2025. This panel and a discussion on neurodegenerative disease research will also be featured at the premier global virtual conference Olink Proteomics World on October 8, 2025.

*For research use only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information: 
Jess King

760-289-8032

Email: jess.king@thermofisher.com

Alex M. Azar II Joins Guardant Health Board of Directors




Alex M. Azar II Joins Guardant Health Board of Directors

PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans’ health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention.

“We’re honored to welcome Secretary Azar to Guardant’s board,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “Secretary Azar has served at the senior-most levels of government as well as the private sector, bringing deep operating experience coupled with a strategic understanding of how policy, innovation and patient access intersect. His perspective will be invaluable as we continue developing new innovations to conquer cancer and working to ensure more patients have access to lifesaving technologies.”

“Guardant pioneered a new category with liquid biopsy and continues to push the boundaries of what is possible as the leading company in the space,” said Secretary Azar. “I look forward to working with the board and leadership team to advance the company’s impact and mission of helping people live longer, healthier lives by catching and managing cancer earlier.”

Prior to his appointment as HHS Secretary, Azar held multiple executive leadership roles including as President of Lilly USA, LLC, the largest affiliate of Eli Lilly and Company, General Counsel of HHS, Deputy Secretary of HHS, and Partner at Wiley Rein LLP. He currently serves as an Adjunct Professor of Business and Distinguished Executive-in-Residence at the University of Miami Patti and Allan Herbert Business School. He also serves as a member of the Board of Trustees at the Aspen Institute, chairman of the board of LifeScience Logistics, a member of the boards of Global Health/MCS, AbsoluteCare, and Interwell Health, and as an advisor at Foresite Capital, a member of the advisory board of Milken Institute’s FasterCures, and a member of the Department of Health Policy Advisory Board at the Stanford University School of Medicine.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Contacts

Investor Contact:
Zarak Khurshid

investors@guardanthealth.com

Media Contact:
Meaghan Smith

press@guardanthealth.com

Atom Therapeutics Enrolls First Patient in Multicenter Global Phase 2 Trial of ABP-745 for Acute Gout Flares




Atom Therapeutics Enrolls First Patient in Multicenter Global Phase 2 Trial of ABP-745 for Acute Gout Flares

ABP-745 is an oral small molecule drug with potential applications, for other inflammatory conditions such as cardiovascular disease

HANGZHOU, China–(BUSINESS WIRE)–Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today it has enrolled the first patient in a multi-country Phase 2 trial of ABP-745, a novel anti-inflammatory drug, for treatment of painful acute gout flares.

Trial sites in the US, China and Australia are expected to enroll more than 200 patients in this randomized, double-blind study to evaluate the safety, efficacy and pharmacodynamics of ABP-745 in reducing the pain and swelling associated with an acute gout flare. ABP-745 dosing regimen will be compared with placebo and colchicine, a standard treatment for gout flares.

Dr. William Dongfang Shi, Founder, Chairman and CEO of Atom Therapeutics, commented, “This study follows a Phase 1 trial in the US demonstrating that ABP-745 is safe and well tolerated and represents significant progress in our development of a new anti-inflammatory drug. ABP-745 was designed as a new chemical entity with the intention of improving efficacy without the concern for key interactions with other medications and better safety than colchicine in the treatment of acute gout flares.”

Dr. Shi added, “While the first clinical indication for ABP-745 is for the treatment of acute gout flares, based on its positive inhibitory effects on various inflammatory factors such as IL-1β, TNF-α, IL-6, and IL-18, it will also be developed for other inflammatory conditions including certain types of cardiovascular disease.”

Acute gout flares are characterized by sudden severe pain and swelling of joints, usually in the lower extremities, triggered by a build-up of urate crystals. The formation of urate crystals is caused by an excessive level of uric acid in the blood usually greater than 7 mg/dL which leads to the development of chronic gout. Most acute gout flares occur in the big toe joint and last for up to seven to ten days before pain and swelling subside. In addition to colchicine, nonsteroidal anti-inflammatory drugs and glucocorticoids are used for the treatment for acute gout flares, but these medications can be associated with serious adverse events such as gastrointestinal discomfort, cardiovascular events, kidney injury, and osteoporosis. Another class of medications used in treatment of gout, IL-1β inhibitors, also have serious side effects such as increased risk of infection, immunosuppression, and allergic reactions.

Gout is caused by hyperuricemia and it is one of the most common types of inflammatory arthritis affecting more than 60 million people worldwide. The disease has a large and growing patient population in the U.S., Europe, Asia and Latin America. Gout affects approximately 12 million patients in the U.S., with an average of 6.6 acute gout flares per year. As many gout flares are not reported, the true burden may be higher, and the number of acute gout flares in the U.S. may exceed 80 million per year.

If hyperuricemia is not controlled, the frequency and severity of acute gout flares may further worsen. Acute gout flares seriously affect the quality of life and safety of patients. Recent research reports have shown that acute gout flares are associated with an increased probability of sudden death caused by cardiovascular disease. Gout can also worsen other serious comorbidities including kidney injury.

Atom’s lead product, lingdolinurad (ABP-671), is an oral small molecule URAT1 inhibitor in global multicenter Phase 2b/3 trials for chronic gout. Positive topline results show ABP-671 has achieved its primary endpoint in lowering patients’ uric acid levels and has demonstrated good safety and tolerability, positioning it as a leading candidate for best-in-class treatment of chronic gout. Read the full press release.

About Atom Therapeutics

Atom Therapeutics Co., Ltd (formerly Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) is a fast-growing innovative clinical stage biotechnology company focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, lingdolinurad (ABP-671), is in late-stage clinical development for treatment of chronic gout. Another small molecule ABP-745, for anti-inflammatory and autoimmune conditions, is in global Phase 2 clinical trials for acute gout.

For more information, please visit: https://atomthera.us/

Contacts

Media Contact:
Daniel Eramian

Opus Biotech Communications

http://opusbiotech.com/
425-306-8716

Business Development Contact:
Roy J. Wu, MBA

Sr. Vice President, Business Development

Atom Therapeutics

Email: roy.wu@atombp.com